Panacea Biotec Reports Nil Dematerialization in April 2026
Panacea Biotec reported no share dematerialization in April 2026. As of April 30, 2026, total dematerialized shares were 6,11,04,526 (NSDL: 5,36,44,500; CDSL: 74,60,026). This update complies with SEBI regulations.
This is a standard disclosure of dematerialization data, which is a routine operational update and is not expected to have any significant impact on the company's stock price.
The announcement is a routine regulatory filing regarding share dematerialization and does not contain any information that would positively or negatively impact the company's stock.
Panacea Biotec Limited has informed the stock exchanges regarding the dematerialization of shares for the month of April 2026. The company stated that no shares were dematerialized during this period.
As of April 30, 2026, the total number of shares dematerialized stood at 6,11,04,526. This comprises 5,36,44,500 shares with NSDL and 74,60,026 shares with CDSL.
The company's Registrar and Share Transfer Agent (RTA), Skyline Financial Services Pvt. Ltd., has provided a certificate confirming these details as of April 30, 2026. The announcement is in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.